New drug cocktail shows promise for untreated leukemia patients

NCT ID NCT07514832

Recruiting now Disease control Sponsor: Beijing 302 Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of five drugs (venetoclax, azacitidine, cytarabine, idarubicin, and G-CSF) as a first treatment for adults aged 18-70 with acute myeloid leukemia (AML) who are healthy enough for strong chemotherapy. The goal is to see how many patients achieve complete remission (cancer disappearance) after two cycles. The study involves 48 participants across multiple centers and tracks side effects and minimal residual disease (tiny leftover cancer cells).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOID LEUKEMIA)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chinese PLA General Hospital
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••